Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 0.83 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.80 |
| ▸ | BCHE | P06276 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6014543 | 1.00 | SIGMAR1 (1.00) | SIGMAR1MAOACHRM2BCHEGAA | |
| SCHEMBL8097260 | 1.00 | SIGMAR1 (1.00) | SIGMAR1MAOACHRM2BCHEGAA | |
| SCHEMBL6014369 | 1.00 | SIGMAR1 (1.00) | SIGMAR1MAOACHRM2BCHEGAA | |
| SCHEMBL7756958 | 1.00 | SIGMAR1 (1.00) | SIGMAR1MAOACHRM2BCHEGAA | |
| SCHEMBL6014422 | 0.98 | SIGMAR1 (1.00) | SIGMAR1MAOACHRM2BCHEGAA | |
| SCHEMBL4065566 | 0.91 | SIGMAR1 (0.88) | SIGMAR1MAOACHRM2BCHEGAA | |
| SCHEMBL4642587 | 0.91 | MAOA (1.00) | SIGMAR1MAOACHRM2GAAMAPT | |
| SCHEMBL16260102 | 0.91 | MAOA (1.00) | SIGMAR1MAOACHRM2GAAMAPT | |
| SCHEMBL7202099 | 0.91 | MAOA (1.00) | SIGMAR1MAOACHRM2GAAMAPT | |
| SCHEMBL8851048 | 0.91 | MAOA (1.00) | SIGMAR1MAOACHRM2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6057371-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS, DRUG ABUSE, ANGINA, MIGRAINE, HYPERTENSION AND DEPRESSION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-05-02 | — | — | US | claimed |
| EP-0591426-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-04-13 | — | — | EP | claimed |
| WO-1993000313-A2 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-01-07 | — | — | WO | claimed |
| WO-1991009594-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1991-07-11 | — | — | WO | claimed |
| EP-3041831-B1 | ALPHA-TEA SALT FORMS: COMPOSITIONS AND USES FOR TREATING DISEASE | RES FOUND DEV (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3251671-A1 | COMPOSITIONS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER | Akebia Therapeutics Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| CN-1300730-A | Process for preparing aminoformate compounds with CO2 instead of severely toxic optical gas | SHANGHAI INST ORGANIC CHEM (CN) | 2001-06-27 | — | — | CN | disclosed |
| US-6057371-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS, DRUG ABUSE, ANGINA, MIGRAINE, HYPERTENSION AND DEPRESSION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-05-02 | — | — | US | disclosed |
| CN-1223670-A | elastomer and preparation method thereof | DOW CHEMICAL CO (US) | 1999-07-21 | — | — | CN | disclosed |
| WO-1996034851-A1 | BENZENE, PYRIDINE, NAPHTALENE OR BENZOPHENONE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-11-07 | — | — | WO | disclosed |
| EP-0591426-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-04-13 | — | — | EP | disclosed |
| WO-1993000313-A2 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-01-07 | — | — | WO | disclosed |